Retrospective  ||| S:0 E:14 ||| JJ
study  ||| S:14 E:20 ||| NN
of  ||| S:20 E:23 ||| IN
clinical  ||| S:23 E:32 ||| JJ
features  ||| S:32 E:41 ||| NNS
of  ||| S:41 E:44 ||| IN
neuromyelitis  ||| S:44 E:58 ||| JJ
optica  ||| S:58 E:65 ||| JJ
spectrum  ||| S:65 E:74 ||| NN
disease  ||| S:74 E:82 ||| NN
with  ||| S:82 E:87 ||| IN
connective  ||| S:87 E:98 ||| JJ
tissue  ||| S:98 E:105 ||| NN
disease  ||| S:105 E:113 ||| NN
To  ||| S:113 E:116 ||| TO
explore  ||| S:116 E:124 ||| VB
the  ||| S:124 E:128 ||| DT
clinical  ||| S:128 E:137 ||| JJ
features  ||| S:137 E:146 ||| NNS
of  ||| S:146 E:149 ||| IN
neuromyelitis  ||| S:149 E:163 ||| JJ
optica  ||| S:163 E:170 ||| NNS
( ||| S:170 E:171 ||| -LRB-
NMO ||| S:171 E:174 ||| NNP
)  ||| S:174 E:176 ||| -RRB-
spectrum  ||| S:176 E:185 ||| NN
disease  ||| S:185 E:193 ||| NN
( ||| S:193 E:194 ||| -LRB-
NMOSD ||| S:194 E:199 ||| NNP
)  ||| S:199 E:201 ||| -RRB-
with  ||| S:201 E:206 ||| IN
connective  ||| S:206 E:217 ||| JJ
tissue  ||| S:217 E:224 ||| NN
disease  ||| S:224 E:232 ||| NN
( ||| S:232 E:233 ||| -LRB-
CTD ||| S:233 E:236 ||| NNP
) ||| S:236 E:237 ||| -RRB-
.  ||| S:237 E:239 ||| .
The  ||| S:239 E:243 ||| DT
clinical  ||| S:243 E:252 ||| JJ
features  ||| S:252 E:261 ||| NNS
of  ||| S:261 E:264 ||| IN
184  ||| S:264 E:268 ||| CD
NMO ||| S:268 E:271 ||| NNP
/ ||| S:271 E:272 ||| NNP
NMOSD  ||| S:272 E:278 ||| NNP
patients  ||| S:278 E:287 ||| NNS
( ||| S:287 E:288 ||| -LRB-
NMO ||| S:288 E:291 ||| NNP
/ ||| S:291 E:292 ||| NNP
NMOSD ||| S:292 E:297 ||| NNP
:  ||| S:297 E:299 ||| :
119 ||| S:299 E:302 ||| CD
/ ||| S:302 E:303 ||| CD
184 ||| S:303 E:306 ||| CD
,  ||| S:306 E:308 ||| ,
64.7 ||| S:308 E:312 ||| CD
% ||| S:312 E:313 ||| NN
;  ||| S:313 E:315 ||| :
NMO ||| S:315 E:318 ||| NNP
/ ||| S:318 E:319 ||| NNP
NMOSD-CTD ||| S:319 E:328 ||| NNP
:  ||| S:328 E:330 ||| :
65 ||| S:330 E:332 ||| CD
/ ||| S:332 E:333 ||| CD
184 ||| S:333 E:336 ||| CD
,  ||| S:336 E:338 ||| ,
35.3 ||| S:338 E:342 ||| CD
% ||| S:342 E:343 ||| NN
)  ||| S:343 E:345 ||| -RRB-
from  ||| S:345 E:350 ||| IN
May  ||| S:350 E:354 ||| NNP
2013  ||| S:354 E:359 ||| CD
to  ||| S:359 E:362 ||| TO
May  ||| S:362 E:366 ||| NNP
2014  ||| S:366 E:371 ||| CD
were  ||| S:371 E:376 ||| VBD
analyzed  ||| S:376 E:385 ||| JJ
retrospectively ||| S:385 E:400 ||| NN
.  ||| S:400 E:402 ||| .
And  ||| S:402 E:406 ||| CC
the  ||| S:406 E:410 ||| DT
effectiveness  ||| S:410 E:424 ||| NN
of  ||| S:424 E:427 ||| IN
long-term  ||| S:427 E:437 ||| JJ
treatment  ||| S:437 E:447 ||| NN
of  ||| S:447 E:450 ||| IN
immunosuppressive  ||| S:450 E:468 ||| JJ
drugs  ||| S:468 E:474 ||| NNS
in  ||| S:474 E:477 ||| IN
NMOSD  ||| S:477 E:483 ||| NNP
was  ||| S:483 E:487 ||| VBD
evaluated ||| S:487 E:496 ||| VBN
.  ||| S:496 E:498 ||| .
NMO ||| S:498 E:501 ||| NNP
/ ||| S:501 E:502 ||| NNP
NMOSD-CTD  ||| S:502 E:512 ||| JJ
patients  ||| S:512 E:521 ||| NNS
had  ||| S:521 E:525 ||| VBD
significantly  ||| S:525 E:539 ||| RB
higher  ||| S:539 E:546 ||| RBR
female  ||| S:546 E:553 ||| JJ
percentage  ||| S:553 E:564 ||| NN
( ||| S:564 E:565 ||| -LRB-
93.8 ||| S:565 E:569 ||| CD
%  ||| S:569 E:571 ||| NN
vs  ||| S:571 E:574 ||| VBD
83.2 ||| S:574 E:578 ||| CD
% ||| S:578 E:579 ||| NN
,  ||| S:579 E:581 ||| ,
P  ||| S:581 E:583 ||| NN
< ||| S:583 E:585 ||| SYM
0.05 ||| S:585 E:589 ||| CD
)  ||| S:589 E:591 ||| -RRB-
and  ||| S:591 E:595 ||| CC
significantly  ||| S:595 E:609 ||| RB
higher  ||| S:609 E:616 ||| JJR
percentage  ||| S:616 E:627 ||| NN
of  ||| S:627 E:630 ||| IN
patients  ||| S:630 E:639 ||| NNS
with  ||| S:639 E:644 ||| IN
cerebral  ||| S:644 E:653 ||| JJ
spinal  ||| S:653 E:660 ||| JJ
fluid  ||| S:660 E:666 ||| NN
( ||| S:666 E:667 ||| -LRB-
CSF ||| S:667 E:670 ||| NNP
) ||| S:670 E:671 ||| -RRB-
-restricted  ||| S:671 E:683 ||| JJ
oligoclonal  ||| S:683 E:695 ||| JJ
band  ||| S:695 E:700 ||| NN
( ||| S:700 E:701 ||| -LRB-
OB ||| S:701 E:703 ||| NNP
) ||| S:703 E:704 ||| -RRB-
( ||| S:704 E:705 ||| -LRB-
41.5 ||| S:705 E:709 ||| CD
%  ||| S:709 E:711 ||| NN
vs  ||| S:711 E:714 ||| VBD
21.9 ||| S:714 E:718 ||| CD
% ||| S:718 E:719 ||| NN
,  ||| S:719 E:721 ||| ,
P  ||| S:721 E:723 ||| NN
< ||| S:723 E:725 ||| SYM
0.05 ||| S:725 E:729 ||| CD
) ||| S:729 E:730 ||| -RRB-
.  ||| S:730 E:732 ||| .
As  ||| S:732 E:735 ||| RB
compared  ||| S:735 E:744 ||| VBN
with  ||| S:744 E:749 ||| IN
NMO ||| S:749 E:752 ||| NNP
/ ||| S:752 E:753 ||| NNP
NMOSD-CTD  ||| S:753 E:763 ||| JJ
counterparts ||| S:763 E:775 ||| NNS
,  ||| S:775 E:777 ||| ,
NMO ||| S:777 E:780 ||| NNP
/ ||| S:780 E:781 ||| NNP
NMOSD  ||| S:781 E:787 ||| NNP
patients  ||| S:787 E:796 ||| NNS
had  ||| S:796 E:800 ||| VBD
significantly  ||| S:800 E:814 ||| RB
higher  ||| S:814 E:821 ||| JJR
percentage  ||| S:821 E:832 ||| NN
of  ||| S:832 E:835 ||| IN
non-specific  ||| S:835 E:848 ||| JJ
lesions  ||| S:848 E:856 ||| NNS
on  ||| S:856 E:859 ||| IN
brain  ||| S:859 E:865 ||| NN
MRI  ||| S:865 E:869 ||| NNP
( ||| S:869 E:870 ||| -LRB-
62.5 ||| S:870 E:874 ||| CD
%  ||| S:874 E:876 ||| NN
vs  ||| S:876 E:879 ||| VBD
35.9 ||| S:879 E:883 ||| CD
% ||| S:883 E:884 ||| NN
,  ||| S:884 E:886 ||| ,
P  ||| S:886 E:888 ||| NN
< ||| S:888 E:890 ||| SYM
0.01 ||| S:890 E:894 ||| CD
) ||| S:894 E:895 ||| -RRB-
.  ||| S:895 E:897 ||| .
After  ||| S:897 E:903 ||| IN
> ||| S:903 E:904 ||| CD
6  ||| S:904 E:906 ||| CD
months  ||| S:906 E:913 ||| NNS
consecutive  ||| S:913 E:925 ||| JJ
long-term  ||| S:925 E:935 ||| JJ
treatment  ||| S:935 E:945 ||| NN
of  ||| S:945 E:948 ||| IN
immunosuppressive  ||| S:948 E:966 ||| JJ
drugs ||| S:966 E:971 ||| NNS
,  ||| S:971 E:973 ||| ,
the  ||| S:973 E:977 ||| DT
relapse  ||| S:977 E:985 ||| JJ
rate  ||| S:985 E:990 ||| NN
post-treatment  ||| S:990 E:1005 ||| NNS
( ||| S:1005 E:1006 ||| -LRB-
0.36  ||| S:1006 E:1011 ||| CD
±  ||| S:1011 E:1013 ||| CD
0.85 ||| S:1013 E:1017 ||| CD
)  ||| S:1017 E:1019 ||| -RRB-
was  ||| S:1019 E:1023 ||| VBD
significantly  ||| S:1023 E:1037 ||| RB
lower  ||| S:1037 E:1043 ||| JJR
than  ||| S:1043 E:1048 ||| IN
that  ||| S:1048 E:1053 ||| DT
pre-treatment  ||| S:1053 E:1067 ||| JJ
( ||| S:1067 E:1068 ||| -LRB-
2.91  ||| S:1068 E:1073 ||| CD
±  ||| S:1073 E:1075 ||| CD
4.10 ||| S:1075 E:1079 ||| CD
,  ||| S:1079 E:1081 ||| ,
P  ||| S:1081 E:1083 ||| NN
< ||| S:1083 E:1085 ||| SYM
0.01 ||| S:1085 E:1089 ||| CD
) ||| S:1089 E:1090 ||| -RRB-
.  ||| S:1090 E:1092 ||| .
And  ||| S:1092 E:1096 ||| CC
no  ||| S:1096 E:1099 ||| DT
significant  ||| S:1099 E:1111 ||| JJ
difference  ||| S:1111 E:1122 ||| NN
existed  ||| S:1122 E:1130 ||| VBD
in  ||| S:1130 E:1133 ||| IN
expanded  ||| S:1133 E:1142 ||| JJ
disability  ||| S:1142 E:1153 ||| NN
status  ||| S:1153 E:1160 ||| NN
scale  ||| S:1160 E:1166 ||| NN
( ||| S:1166 E:1167 ||| -LRB-
EDSS ||| S:1167 E:1171 ||| NNP
)  ||| S:1171 E:1173 ||| -RRB-
score  ||| S:1173 E:1179 ||| NN
between  ||| S:1179 E:1187 ||| IN
pre-and  ||| S:1187 E:1195 ||| JJ
post-treatment ||| S:1195 E:1209 ||| NN
.  ||| S:1209 E:1211 ||| .
When  ||| S:1211 E:1216 ||| WRB
using  ||| S:1216 E:1222 ||| VBG
azathioprine  ||| S:1222 E:1235 ||| NNS
( ||| S:1235 E:1236 ||| -LRB-
AZA ||| S:1236 E:1239 ||| NNP
) ||| S:1239 E:1240 ||| -RRB-
,  ||| S:1240 E:1242 ||| ,
the  ||| S:1242 E:1246 ||| DT
percentage  ||| S:1246 E:1257 ||| NN
of  ||| S:1257 E:1260 ||| IN
relapse  ||| S:1260 E:1268 ||| NN
was  ||| S:1268 E:1272 ||| VBD
significantly  ||| S:1272 E:1286 ||| RB
higher  ||| S:1286 E:1293 ||| JJR
in  ||| S:1293 E:1296 ||| IN
NMO ||| S:1296 E:1299 ||| NNP
/ ||| S:1299 E:1300 ||| NNP
NMOSD-CTD  ||| S:1300 E:1310 ||| JJ
patients  ||| S:1310 E:1319 ||| NNS
( ||| S:1319 E:1320 ||| -LRB-
50.0 ||| S:1320 E:1324 ||| NNP
% ||| S:1324 E:1325 ||| NN
)  ||| S:1325 E:1327 ||| -RRB-
versus  ||| S:1327 E:1334 ||| FW
NMO ||| S:1334 E:1337 ||| FW
/ ||| S:1337 E:1338 ||| FW
NMOSD  ||| S:1338 E:1344 ||| FW
ones  ||| S:1344 E:1349 ||| FW
( ||| S:1349 E:1350 ||| -LRB-
18.5 ||| S:1350 E:1354 ||| CD
% ||| S:1354 E:1355 ||| NN
,  ||| S:1355 E:1357 ||| ,
P  ||| S:1357 E:1359 ||| NN
=  ||| S:1359 E:1361 ||| SYM
0.064 ||| S:1361 E:1366 ||| CD
) ||| S:1366 E:1367 ||| -RRB-
;  ||| S:1367 E:1369 ||| :
When  ||| S:1369 E:1374 ||| WRB
using  ||| S:1374 E:1380 ||| VBG
cyclophosphamide  ||| S:1380 E:1397 ||| NNS
( ||| S:1397 E:1398 ||| -LRB-
CTX ||| S:1398 E:1401 ||| NNP
) ||| S:1401 E:1402 ||| -RRB-
,  ||| S:1402 E:1404 ||| ,
there  ||| S:1404 E:1410 ||| EX
was  ||| S:1410 E:1414 ||| VBD
no  ||| S:1414 E:1417 ||| DT
such  ||| S:1417 E:1422 ||| JJ
significant  ||| S:1422 E:1434 ||| JJ
difference ||| S:1434 E:1444 ||| NN
.  ||| S:1444 E:1446 ||| .
Female  ||| S:1446 E:1453 ||| JJ
patients  ||| S:1453 E:1462 ||| NNS
are  ||| S:1462 E:1466 ||| VBP
more  ||| S:1466 E:1471 ||| RBR
susceptible  ||| S:1471 E:1483 ||| JJ
to  ||| S:1483 E:1486 ||| TO
have  ||| S:1486 E:1491 ||| VB
NMO ||| S:1491 E:1494 ||| NNP
/ ||| S:1494 E:1495 ||| NNP
NMOSD  ||| S:1495 E:1501 ||| NNP
with  ||| S:1501 E:1506 ||| IN
CTD ||| S:1506 E:1509 ||| NNP
.  ||| S:1509 E:1511 ||| .
NMO ||| S:1511 E:1514 ||| NNP
/ ||| S:1514 E:1515 ||| NNP
NMOSD-CTD  ||| S:1515 E:1525 ||| JJ
patients  ||| S:1525 E:1534 ||| NNS
tend  ||| S:1534 E:1539 ||| VBP
to  ||| S:1539 E:1542 ||| TO
have  ||| S:1542 E:1547 ||| VB
higher  ||| S:1547 E:1554 ||| JJR
percentage  ||| S:1554 E:1565 ||| NN
of  ||| S:1565 E:1568 ||| IN
CSF-restricted  ||| S:1568 E:1583 ||| NNP
OB  ||| S:1583 E:1586 ||| NNP
and  ||| S:1586 E:1590 ||| CC
fewer  ||| S:1590 E:1596 ||| JJR
non-specific  ||| S:1596 E:1609 ||| JJ
lesions  ||| S:1609 E:1617 ||| NNS
on  ||| S:1617 E:1620 ||| IN
brain  ||| S:1620 E:1626 ||| NN
MRI ||| S:1626 E:1629 ||| NNP
.  ||| S:1629 E:1631 ||| .
AZA  ||| S:1631 E:1635 ||| NNP
and  ||| S:1635 E:1639 ||| CC
CTX  ||| S:1639 E:1643 ||| NNP
may  ||| S:1643 E:1647 ||| MD
effectively  ||| S:1647 E:1659 ||| RB
reduce  ||| S:1659 E:1666 ||| VB
relapses  ||| S:1666 E:1675 ||| VBN
in  ||| S:1675 E:1678 ||| IN
both  ||| S:1678 E:1683 ||| DT
NMO ||| S:1683 E:1686 ||| NNP
/ ||| S:1686 E:1687 ||| NNP
NMOSD  ||| S:1687 E:1693 ||| NNP
and  ||| S:1693 E:1697 ||| CC
NMO ||| S:1697 E:1700 ||| NNP
/ ||| S:1700 E:1701 ||| NNP
NMOSD-CTD  ||| S:1701 E:1711 ||| JJ
patients ||| S:1711 E:1719 ||| NNS
.  ||| S:1719 E:1721 ||| .
However  ||| S:1721 E:1729 ||| RB
CTX  ||| S:1729 E:1733 ||| NNP
is  ||| S:1733 E:1736 ||| VBZ
superior  ||| S:1736 E:1745 ||| JJ
to  ||| S:1745 E:1748 ||| TO
AZA  ||| S:1748 E:1752 ||| NNP
for  ||| S:1752 E:1756 ||| IN
reducing  ||| S:1756 E:1765 ||| VBG
relapses  ||| S:1765 E:1774 ||| NN
in  ||| S:1774 E:1777 ||| IN
NMO ||| S:1777 E:1780 ||| NNP
/ ||| S:1780 E:1781 ||| NNP
NMOSD-CTD  ||| S:1781 E:1791 ||| JJ
patients ||| S:1791 E:1799 ||| NNS
.  ||| S:1799 E:1801 ||| .
